Get the Stockscreener App
24.27
1.15%
0.285
Elanco Animal Health Inc stock is traded at $24.27, with a volume of 1.31M.
It is up +1.15% in the last 24 hours and up +11.26% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
See More
Previous Close:
$23.98
Open:
$23.99
24h Volume:
1.31M
Relative Volume:
0.23
Market Cap:
$12.12B
Revenue:
$4.72B
Net Income/Loss:
$-232.00M
P/E Ratio:
-52.04
EPS:
-0.4663
Net Cash Flow:
$284.00M
1W Performance:
+11.62%
1M Performance:
+11.26%
6M Performance:
+4.23%
1Y Performance:
+79.40%
1-Day Range:
$23.74
$24.32
1-Week Range:
$21.63
$24.40
52-Week Range:
$13.09
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
24.26 | 11.98B | 4.72B | -232.00M | 284.00M | -0.4663 |
TAK
Takeda Pharmaceutical Co Adr
|
16.04 | 51.03B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.34 | 40.20B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.19 | 40.78B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.73 | 32.81B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
555.41 | 23.86B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Animal Health 2026 Shareholder Meeting Results: Board Elections and Executive Compensation Vote - Minichart
A Look at Elanco Animal Health Inc (ELAN) After 3.8% Gain -- GF Value $15.53 vs Price $23.69 - GuruFocus
Elanco (NYSE: ELAN) investors reelect board and ratify 2026 auditor - Stock Titan
Monumental Public-Private Initiative Forms to Permanently Close America’s Protein Gap - CSRwire
A Look at Elanco Animal Health Inc (ELAN) After 5.0% Gain -- GF Value $15.53 vs Price $22.82 - GuruFocus
Board member at Elanco (NYSE: ELAN) granted new equity awards - Stock Titan
Elanco (NYSE: ELAN) director receives deferred and restricted stock units - Stock Titan
Elanco Animal Health (ELAN) director granted new equity awards - Stock Titan
[Form 4] Elanco Animal Health Inc Insider Trading Activity - Stock Titan
Elanco (NYSE: ELAN) director receives 4,678 deferred stock units - Stock Titan
Board member gets 4,678-share equity award at Elanco (NYSE: ELAN) - Stock Titan
Elanco (ELAN) director Harrington granted deferred and restricted stock units - Stock Titan
Elanco (ELAN) director granted stock and deferred unit awards as compensation - Stock Titan
Elanco (NYSE: ELAN) director Stacey Ma receives annual equity grants - Stock Titan
Elanco (NYSE: ELAN) director granted deferred and restricted stock units - Stock Titan
Elanco Animal Health (ELAN) Stock Analysis: Exploring Potential 37% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Q1 2026 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks - Yahoo Finance
ELAN Stock Price, Quote & Chart | ELANCO ANIMAL HEALTH INC (NYSE:ELAN) - ChartMill
Elanco Animal Health Inc Annual Shareholders Meeting Transcript - GuruFocus
Elanco Launches Befrena As New Dermatology Driver For Undervalued Shares - Yahoo Finance
Companion Animal Health Market is expected to Hit US$ 56.60 - openPR.com
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? - GuruFocus
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? GF Value Says Overvalued - GuruFocus
Elanco CEO Jeffrey Simmons buys $99,842 in company stock By Investing.com - Investing.com South Africa
Elanco EVP Rajeev Modi buys $99,938 of company stock By Investing.com - Investing.com South Africa
Elanco EVP Rajeev Modi buys $99,938 of company stock - Investing.com UK
Elanco CEO Jeffrey Simmons buys $99,842 in company stock - Investing.com UK
Elanco (NYSE: ELAN) officer Modi buys shares and receives deferred stock units - Stock Titan
Elanco (NYSE: ELAN) CEO adds shares and receives deferred units - Stock Titan
Elanco (NYSE: ELAN) CFO receives grant of deferred stock units as compensation - Stock Titan
Elanco Animal Health Launches Canine Dermatitis Drug Befrena - Moomoo
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets - Investing.com India
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets By Investing.com - Investing.com Nigeria
Elanco (ELAN) Launches New Canine Allergy Treatment Befrena - GuruFocus
Elanco launches canine dermatitis treatment Befrena in U.S. By Investing.com - Investing.com Canada
New dog allergy shot from Elanco offers 6–8 weeks of itch relief - Stock Titan
Elanco Animal Health (ELAN) Stock Report: A Healthcare Stock with Nearly 50% Upside Potential - DirectorsTalk Interviews
Elanco Q1 2026 Earnings: Revenue $1.37B, EPS $0.40, Guidance RaisedNews and Statistics - IndexBox
5 Insightful Analyst Questions From Elanco’s Q1 Earnings Call - Yahoo Finance
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Scor - GuruFocus
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Score of 70 Tells Investors - GuruFocus
Elanco finalizes acquisition of AHV International - Feed Strategy
Morgan Stanley Maintains Elanco Animal Health(ELAN.US) With Hold Rating, Raises Target Price to $23 - Moomoo
Elanco to Participate in Investor Conferences - Intellectia AI
Elanco to Participate in Upcoming Investor Conferences - GuruFocus
Dodge & Cox holds 13.9% of Elanco (NYSE: ELAN) in 13G/A amendment - Stock Titan
How to listen in as Elanco execs talk to investors in May and June - Stock Titan
Elanco reaches $9.3M settlement with consumers over antitrust allegations involving flea and tick products - Indianapolis Business Journal
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):